A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Cytarabine (Primary) ; Ibrutinib (Primary) ; Idarubicin (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- 24 Aug 2017 Status changed from suspended to recruiting.
- 24 Apr 2017 Status changed from recruiting to suspended due to Regulatory.
- 08 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 May 2018.